FA0.F PExA AB (publ)
- Market cap
- EUR 4.49M
- P/E
- -
- P/B
- 5.52x
- ROE
- -52.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is FA0.F undervalued?
Graham numberThe Graham number of PExA AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PExA AB (publ) fundamental analysis
No fundamental analysis for PExA AB (publ) yet.
PExA AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PExA AB (publ)
PExA AB (publ) develops and commercializes diagnostic products for various respiratory diseases. It offers products for asthma, tuberculosis, cystic fibrosis, lung cancer, and chronic obstructive pulmonary disease. The company's research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. It offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air. The company also pr…
Full company profilePExA AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PExA AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.16M | 6.03M | 2.02M | 720K | 478K | 2.38M |
| Gross Profit | 1.36M | 5.07M | 527K | 326K | 2.99M | 4.37M |
| Operating Income | -7.80M | -4.44M | -8.52M | -10.5M | -6.33M | -4.46M |
| EBITDA | - | -3.75M | -7.68M | -9.85M | -5.82M | -4.05M |
| Net Income | -7.76M | -4.31M | -8.04M | -10.2M | -6.25M | -4.40M |
| EPS | -0.17 | -0.07 | -0.14 | -0.13 | -0.05 | -0.03 |
| Balance Sheet | ||||||
| Total Assets | 26.3M | 24.9M | 15.1M | 10.2M | 13.5M | 16.0M |
| Total Liabilities | 4.40M | 3.62M | 1.92M | 1.96M | 2.82M | 7.52M |
| Shareholders' Equity | 21.9M | 21.3M | 13.2M | 8.23M | 10.7M | 8.47M |
| Cash & Short-term Investments | 20.7M | 18.2M | 9.60M | 5.59M | 6.24M | 796K |
| Cash Flow | ||||||
| Operating Cash Flow | -5.19M | -5.50M | -9.47M | -8.32M | -3.79M | -6.83M |
| Capital Expenditure | 853K | 637K | 0.00 | 850K | 4.25M | 4.05M |
| Free Cash Flow | -6.05M | -6.14M | -9.47M | -9.17M | -8.04M | -10.9M |
| Ratios | ||||||
| ROE | -35.4% | -20.2% | -60.8% | -123.5% | -58.6% | -52.0% |
| ROA | -29.5% | -17.3% | -53.1% | -99.8% | -46.3% | -27.5% |
| Net Profit Margin | -359.0% | -71.4% | -399.1% | -1,412.2% | -1,307.8% | -185.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PExA AB (publ) dividends
PExA AB (publ) has not paid dividends in the last 5 fiscal years.
Who owns PExA AB (publ)
- Insiders 9.50%
- Institutions 6.64%
- Public & others 83.85%
- Shares outstanding 206M
- Free float 119M
PExA AB (publ) company profile
- Company name
- PExA AB (publ)
- Ticker
- FA0.F
- ISIN
- SE0007412374
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 3
- Fiscal year end
- December
- Address
- Arvid Wallgrens Backe 20, Gothenburg, Sweden, 413 46
- Phone
- 46 7 05 86 43 80
- Website
- pexa.se
About PExA AB (publ)
PExA AB (publ) develops and commercializes diagnostic products for various respiratory diseases. It offers products for asthma, tuberculosis, cystic fibrosis, lung cancer, and chronic obstructive pulmonary disease. The company's research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. It offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air. The company also provides accessories, which include substrate surfaces and nozzles, as well as parts and service kits. It provides products for lung research centers within the health services, academia, and pharmaceutical companies. The company was founded in 2004 and is based in Gothenburg, Sweden.
PExA AB (publ) management
3- Mr. Tomas GustafssonMD & CEO · born 1971
- Ms. Anna-Carin OlinFounder, Research Director & Director · born 1960
- Mr. Jörgen ÖstlingC.S.O · born 1962